The challenge: Metastasis
For longer than half a century, Science has achieved remarkable success in diagnosing and managing the early stages of cancer. But metastatic solid tumors are still an unmet medical need. From classical small molecules to modern immunotherapy, every approach has failed to treat solid tumors as Colorectal or Pancreatic Cancer when metastasis arises.
Metastatic Colorectal Cancer (CRC) patients with microsatellite-stable (MSS) tumors respond poorly to Immune Checkpoint Inhibitors treatment. N. Engl. J. Med. 372, 2509-2520 (2015). Lancet Oncol. 18, 1182-1191 (2017). No MSS CRC patients with liver or peritoneal metastasis benefit from immunotherapy, even in combination with multitargeted tyrosine kinase inhibitors (TKI). J. Clin. Oncol. 38, 2053-2061 (2020). JAMA Network Open 4, e2118416 (2021).
Immunotherapy in metastatic Pancreatic Cancer, either as a single agent or in combo with chemotherapy, has shown very limited benefit outside of the rare mismatch repair deficient tumors. Possible explanations for such immune resistance include tumor microenvironment factors, such as the presence of cancer associated fibroblasts (CAFs). Renouf, D.J. et al. Nat. Commun. 13, 5020 (2022). O’Reilly, E. M. et al. JAMA Oncol. 5, 1431–1438 (2019). Monteran, L. & Erez, N. Front. Immunol. 10, 1835 (2019).
CAFS
Our approach: Targeting CAFs in the Tumor Microenvironment.
The Tumor Microenvironment is a complex and heterogeneous network of extracellular matrix, soluble cytokines, chemokines, proteases, cancer-associated fibroblasts, endothelial and immune cells. Cancer Associated Fibroblasts (CAFs) in the tumor microenvironment are in constant interaction with the tumor cells. CAFs play a key role in tumor invasion, growth, metastasis and immune suppression.
Oncomatryx has developed unique Antibody Drug Conjugates that target CAFs in the tumor microenvironment, as monotherapies or in combination with existing chemotherapies and immunotherapies.
Oncomatryx CAF-targeting ADCs bear a novel mechanism of action, delivering targeted chemotherapy and promoting anti-tumoral immune response.
Oncomatryx CAF-targeting ADCs are showing an unbeatable safety profile and an outstanding efficacy in murine models and clinical trials.
QUANTUM IMMUNOTHERAPY
Pioneering Quantum Immunotherapy
Immune cold tumors are characterized by their resistance to immunotherapy. Cancer-associated fibroblasts (CAFs) play a key role, secreting immunosuppressive interleukins into the tumor microenvironment and blocking cytotoxic immune cells infiltration.
OMTX705 redefines this landscape by targeting CAFs to disrupt their immunosuppressive influence on the tumor cells. This innovative approach transforms immune-cold tumors into immune-hot tumors, enabling immune cells to infiltrate and attack the tumor.
By blocking CAF-mediated secretion of immunosuppressive interleukins and delivering a cytotoxic payload that kills bystander tumor cells and generates tumor neoantigens, OMTX705 stimulates a robust immune response, closing the loop to sustain an immune-hot tumor state.
This revolutionary therapy bridges the gap between immune resistance and immune activation, offering a new horizon in cancer treatment.
